Pulmonary toxicities of tyrosine kinase inhibitors.

Abstract

The incidence of pulmonary toxicities with the use of tyrosine kinase inhibitors (TKIs) is not very high; however, various case reports and studies continue to show significant variability in the incidence of these adverse events, ranging from 0.2% to 10.9%. Gefitinib and erlotinib are orally active, small-molecule inhibitors of the epidermal growth factor… (More)

2 Figures and Tables

Topics

  • Presentations referencing similar topics